Marketing a Retatrutide Program Compliantly: What You Can Say, What You Cannot, and How to Fill Your Program

Marketing a retatrutide program is fundamentally different from marketing a program built around FDA-approved medications. The investigational status of the compound creates specific constraints on what you can say in your marketing — and violating those constraints creates regulatory and legal exposure that can undermine the entire program. Here is how to fill your program compliantly.

You cannot make efficacy claims based on the TRIUMPH trial data as if they apply to your program. The TRIUMPH trials were conducted under controlled conditions with a specific patient population, standardized dosing, and rigorous monitoring. Representing to prospective patients that they will achieve 24% weight loss because that is what the trial showed is a misleading claim — and potentially an FTC violation.

You cannot represent retatrutide as an approved medication. It is not. Any marketing that implies FDA approval — directly or by omission — is false advertising.

You cannot make comparative efficacy claims against approved medications without appropriate qualification. Saying "retatrutide is more effective than Wegovy" in a marketing context, without disclosing the investigational status and the limitations of the comparison, is problematic.

You cannot use patient testimonials that make specific outcome claims. "I lost 40 pounds in 6 months" is a specific outcome claim. FTC guidelines require that testimonials reflect typical results or be accompanied by a clear disclosure of what typical results are. For an investigational compound, typical results are not established.

You can describe the research context accurately. "Our practice participates in IRB-approved research on investigational weight loss compounds" is accurate and appropriate.

You can describe the clinical rationale. "Retatrutide is a triple agonist that targets three metabolic pathways simultaneously, compared to the one or two pathways targeted by currently approved medications" is a factual description of the pharmacology.

You can reference the published trial data with appropriate context. "Phase 3 clinical trial data has shown promising results for retatrutide in obesity treatment" is accurate. Citing the specific data with appropriate qualifications about the investigational status is acceptable.

You can describe your program's clinical infrastructure. "Our program includes structured monitoring, regular follow-up visits, and a dedicated clinical team" is a description of your services, not a claim about the compound.

You can describe the patient population you are targeting. "We are enrolling patients who have not achieved adequate response to currently approved GLP medications" is an accurate description of your inclusion criteria.

The most effective channel for filling a retatrutide program is your existing patient base — specifically, patients who are currently on or have previously been on semaglutide or tirzepatide and have not achieved their weight loss goals.

These patients already understand the GLP category. They have demonstrated willingness to invest in a weight loss program. They have a clear clinical rationale for escalating to a more potent option. And they trust you — they are already your patients.

A simple outreach to your existing GLP patient base, describing the availability of a research program for patients who have not achieved adequate response to current therapies, will generate more qualified inquiries than any external marketing campaign.

The second most effective channel is physician referrals. Primary care physicians, endocrinologists, and obesity medicine specialists who are not running their own retatrutide programs will refer patients who are asking about more potent options. Building relationships with referring physicians — and educating them about your program's compliance framework — is a sustainable patient acquisition strategy.

If you use digital marketing to promote your retatrutide program, work with a healthcare marketing attorney to review your ad copy before it runs. Google and Meta have specific policies about advertising investigational medications, and violating those policies can result in account suspension. More importantly, ad copy that makes inappropriate efficacy claims creates FTC and state consumer protection exposure.

The safest digital marketing approach is to market your practice's weight loss program generally — emphasizing your clinical expertise, your compliance infrastructure, and your track record — and to discuss retatrutide specifically only in the context of a consultation with a qualified patient.

For a retatrutide program, the consultation is where the conversion happens — not the marketing. Your marketing should generate inquiries from qualified patients. The consultation is where you explain the research framework, the consent process, the monitoring requirements, and the clinical rationale for this specific patient. A patient who goes through a thorough consultation and chooses to enroll is a committed research subject who understands what they are signing up for. That is the patient you want in your program.